Market Indices
Sector Heatmap
CMPX — Compass Therapeutics, Inc. Common Stock
NasdaqCompass Therapeutics, Inc. Common Stock
- O
- 0.94
- H
- 0.98
- L
- 0.83
- V
- 20.68M
CMPX — Latest News & Headlines
20 Stories$CMPX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
$CMPX stock is down 13% today. Here's what we see in our data. Quiver Quantitative
Why Did Compass Therapeutics Stock Plunge Today? - Compass Therapeutics (NASDAQ:CMPX) - benzinga.com
Why Did Compass Therapeutics Stock Plunge Today? - Compass Therapeutics (NASDAQ:CMPX) benzinga.com
CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing - Stocktwits
CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing Stocktwits
At $0.92 a share, Compass Therapeutics (CMPX) accounting chief buys 20,000 shares. - Stock Titan
At $0.92 a share, Compass Therapeutics (CMPX) accounting chief buys 20,000 shares. Stock Titan
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) Seeking Alpha
Compass Therapeutics Shares Drop After Downgrade From Wedbush - Yahoo Finance
Compass Therapeutics Shares Drop After Downgrade From Wedbush Yahoo Finance
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares - Investing.com
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares Investing.com
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ - TradingView
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ TradingView
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares - GuruFocus
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares GuruFocus
Compass shares fall after FDA tovecimig feedback - grafa.com
Compass shares fall after FDA tovecimig feedback grafa.com
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position - Stock Titan
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position Stock Titan
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About? Kalkine Media
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside - Yahoo Finance
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside Yahoo Finance
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) Seeking Alpha
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ - Stocktwits
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ Stocktwits
The FDA recommended a trial to show patients live longer. Compass says its current study is enough. - Stock Titan
The FDA recommended a trial to show patients live longer. Compass says its current study is enough. Stock Titan
CMPX Feb 2027 1.500 put (CMPX270219P00001500) Stock Price, News, Quote & History - Yahoo! Finance Canada
CMPX Feb 2027 1.500 put (CMPX270219P00001500) Stock Price, News, Quote & History Yahoo! Finance Canada
Compass says FDA seeks additional trial for lead asset (CMPX) - Seeking Alpha
Compass says FDA seeks additional trial for lead asset (CMPX) Seeking Alpha
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 - Yahoo Finance
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 Yahoo Finance
Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares By Investing.com - Investing.com Nigeria
Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares By Investing.com Investing.com Nigeria